What Your Blood Sugar Has to Do With Cancer (And Why Your Oncologist Never Mentioned It)

There is a conversation happening in integrative oncology that most people with cancer never get to have with their conventional medical team.

It is not about a new drug. It is not about a clinical trial. It is about glucose – the sugar in your blood – and the profound role it plays in creating the conditions that allow cancer to grow, spread, and recur.

This is not fringe science. The relationship between blood sugar dysregulation and cancer has been documented in peer-reviewed research for decades. And yet most people leave their oncologist’s office with a treatment plan that never once addresses what they are eating, what their fasting insulin looks like, or how their body is managing glucose on a cellular level.

Here is what you deserve to know.

Cancer is a glucose-dependent disease.

In 1931, German biochemist Otto Warburg won the Nobel Prize for discovering that cancer cells metabolize glucose differently than healthy cells. While normal cells use oxygen to produce energy efficiently through a process called oxidative phosphorylation, cancer cells preferentially ferment glucose even when oxygen is available. This is known as the Warburg Effect.

What this means practically is that cancer cells are voracious consumers of sugar. They have significantly more insulin receptors than healthy cells, which means they respond aggressively to elevated insulin levels. When blood sugar is high and insulin is elevated – which is the case for a significant portion of the American population due to diet, stress, and sedentary lifestyle – you are quite literally feeding the environment that cancer thrives in.

Insulin is not just about diabetes.

Most people think of insulin as a diabetes issue. But elevated insulin, even in people who do not have diabetes, is one of the most underappreciated drivers of cancer risk and cancer progression.

Insulin is a growth-promoting hormone. When it is chronically elevated, it stimulates cell proliferation, suppresses apoptosis (the natural process by which damaged cells are supposed to die), and promotes inflammation – all of which create favorable conditions for cancer. Research has consistently shown that elevated fasting insulin and insulin resistance are associated with increased risk for breast, colon, pancreatic, and endometrial cancers, among others.

And yet fasting insulin is not a standard part of most oncology lab panels.

What blood sugar dysregulation looks like in the body.

You do not have to have diabetes for this to be relevant to you. Blood sugar dysregulation exists on a spectrum. It includes:

Insulin resistance, where cells stop responding efficiently to insulin and the pancreas compensates by producing more. Reactive hypoglycemia, where blood sugar drops sharply after meals, triggering cortisol and adrenaline responses that further stress the body. Elevated fasting glucose, which indicates that the body is struggling to regulate sugar even in a fasted state. High HbA1c, a marker of average blood sugar over three months that most oncologists never order.

Each of these patterns creates a biochemical environment that is more hospitable to cancer growth. And each of them is addressable through targeted nutrition, lifestyle medicine, and in some cases supplementation.

What naturopathic oncology does differently.

When Dr. Suhaila works with a patient, blood sugar regulation is one of the first areas assessed. This includes fasting glucose, fasting insulin, HbA1c, and a careful look at dietary patterns that may be driving dysregulation without the patient even knowing it.

From there, an individualized protocol is built. This may include a low-glycemic or ketogenic dietary approach tailored to your specific cancer type, targeted supplementation to support insulin sensitivity, strategies to reduce the cortisol-driven glucose spikes that come from chronic stress, and movement protocols that improve cellular glucose uptake without depleting an already taxed system.

This is not about eating perfectly or eliminating all pleasure from food. It is about understanding that what you eat has a direct impact on the biochemical terrain of your body – and that terrain either supports your healing or undermines it.

The question worth asking.

If cancer cells are preferentially fueled by glucose, and if elevated insulin creates a biochemical environment that promotes cancer growth, then addressing blood sugar is not a lifestyle suggestion. It is a metabolic strategy with real clinical implications.

You deserve to have this conversation as part of your care.

If you are ready to look at your terrain from this angle, we are here.